MTOR and cancer: We investigated whether the inhibitory effect of 3039-0164 on PRMT5 affected the activation of the AKT, ERK, and mTOR signaling pathways to learn more about the mechanism of cancer inhibition and the inhibitory effect of 3039-0164.